top of page
microspheres3.jpg

About us

Overview

T Cell Nouveau Inc. is a clinical stage biopharmaceutical company aspiring to cure solid tumors with our novel Hybrid CAR-T cell therapies that enhances the immune system with state of the art technology originated in prof. Hiroshi Shiku laboratory at Mie University.

 

We strongly believe that our unique Hybrid CAR T-cell therapy is a quantum leap toward curing solid tumors, uncovered by modern CAR / TCR-T cell therapies.

 

Our proprietary Hybrid CAR antibodies are highly specific against target antigens (MAGE-A4 and PRAME) in peptide-MHC complexes.

Moreover, our proprietary signal domain constructs help to activate, maintain and prolong T cell effect in immunosuppressive tumor microenvironment.  

 

We are proudly delivering this unique technology from prof. Hiroshi Shiku laboratory at Mie University to global medical practice.

​​

Company vision

Release cell inner power with high precision to strike out cancer

Overview
Message

CEO Message

Our company started on January 15, 2021 as a spin-out venture from Prof. Shiku Laboratory at Mie University Personalized Cancer Immunotherapy Dept.  Although our founder, Dr. Hiroshi Shiku, passed away suddenly on September 4th, 2022, we carry his legacy aiming to deliver his cancer immunotherapy research results to patients. 

CAR T cell therapy based on gene editing technology has been developed over many years since in 1989. In 2017, Kymriah was firstly approved in the United States (and in Japan in 2019), and since then, several CAR-T therapies have been approved for clinical use.

 

However, these are all for blood cancers, and they have not yet been successful for solid cancers.

We aim to further evolve the research achievements of the prof. Shiku Laboratory to bring a new CAR/TCR T cell therapy for solid tumors from Japan to global clinical practice.

Executive Team

Chairman & CEO

Kazuto Takesako

President & COO

Kiyoshi Inoguchi

Director (external)

Kei Fujioka

CEO, Takt Pharma Inc.

Advisor, DBJ Capital

Auditor

Yoshiyuki Wakahara

CEO, Cheers International Inc.

Team

Company Profile

Company name      

T Cell Nouveau Inc.

Company establishment        

January 15, 2021

Headquarter

 

1-6-13-204 Kyobashi, Chuo-ku, Tokyo 104-0031, Japan

Mie University Intergrated Research Building II Room 408  

1577 Kurimamachiya-machi, Tsu, Mie 514-8507, Japan

Joint Research Laboratory

Company Profile
Leadership

Executive Profiles

竹迫takesako.JPG

Kazuto Takesako, Ph.D.

CEO

Prior to co-founding        T Cell Nouveau Inc., built a career in research and development of pharmaceuticals and cancer immunothera-peutics starting from a chief researcher and deputy director of the Biotechnology Research Institute of Takara Shuzo Co., Ltd. from 1976. As an executive officer and senior managing director of Takara Bio Co., Ltd., oversaw the gene therapy drug business in 2002 - 2019,   Currently,  a visiting professor at Mie University and CEO of Cell Consulting.  

Ph.D. from the Department of Agricultural Chemistry, University of Tokyo.

Inoguchi.jpg

Kiyoshi Inoguchi, Ph.D.

COO

Prior to co-founding        T Cell Nouveau Inc.,  engaged in synthetic research at Kaken Pharmaceutical Co., Ltd. in 1992. Assigned to the United States n 2001, he was in charge of business development and alliance promotion. His responsibility ranged from from the conclusion of a license agreement to obtaining approval and launching multiple products.

Ph.D.  in Pharmacy from the Graduate School of Pharmaceutical Sciences, University of Shizuoka.

Scientific Advisory Board

宮原 慶裕 三重大学

Yoshihiro Miyahara, M.D., Ph,D.

Professor

Department of Personalized Cancer Immunotherapy

Mie University Graduate School of Medicine

After graduation from Mie University School of Medicine, Dr. Miyahara entered the Second Department of Internal Medicine.

He conducted research at Baylor College of Medicine (Houston, Texas) and then Toledo University (Toledo, Ohio). After returning to Japan, he started his work as a lecture at Department of Cancer Vaccine, Mie University Graduate School of Medicine. From May 2016, he worked as associate professor at Department of Immuno-Gene Therapy. From March 2018, he has been working as associate professor and promoted to professor at Department of Personalized Cancer Immunotherapy.

Dr. Miyahara`s current research interests are analysis of immune responses and development of effective personalized cancer immunotherapy.

Fujiwara-sensei_edited2_edited_edited_edited.jpg

Hiroshi Fujiwara, M.D., Ph.D.

Professor

Department of Personalized Cancer Immunotherapy

Mie University Graduate School of Medicine

Dr. Fujiwara is majoring hematology, oncology, immunology and allogeneic hematopoietic stem cell transplantation from 1986. Clinically he also has been qualified as specialist of internal medicine, hematology, oncology and hematopoietic stem cell transplantation. He had been a research associate at National Heart, Lung and Blood Institute (NHLBI) / National Institute of Health (NIH) from 2001 to 2004 under the mentorship of Dr. John Barrett. He received Van Bekkum Award at the 37th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in 2011 (entitled Engineered T-lymphocytes using a novel anti-leukemia antigen, Aurora-A kinase-specific T-cell receptor gene transfer successfully displayed anti-leukemia reactivity. Blood 2012 ) He has published more than 100 articles in this field, and has more than 2500 citations so far. He joined Department of Personalized Cancer Immunotherap of Mie University Graduate School of Medicine from July 1st, 2018, and his research interest is currently focused on the development of anticancer adoptive immunotherapy using TCR/CAR gene-modified immune cells and related technological advancement.

Scientific
Strategic partners

Strategic Partners

Mie_logo.JPG

Mie University

World and Japan leading oncoimminology laboratory,  which has been successfully promoting  high level  research to the global innovation frontier for decades while cooperating with leading industry partners as well as public  institutions.

bottom of page